Information Provided By:
Fly News Breaks for November 12, 2018
IOVA
Nov 12, 2018 | 09:02 EDT
B. Riley FBR analyst Madhu Kumar reiterates a Buy rating on Iovance Biotherapeutics with a $24 price target after the company presented Phase II lifileucel melanoma data this weekend. The analyst views the 30% confirmed overall response rate and early duration of response as "impressive" for the highly refractory post-PD-1 patients studied. The analyst says these results validate his optimism for the potentially registrational cohort 4 of lifileucel in melanoma, guided to start in early 2019.
News For IOVA From the Last 2 Days
There are no results for your query IOVA